Teva drops development of laquinimod
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Read More
Tag: Huntington’s
UCL researchers identify Huntington’s disease biomarker
Research led by scientists at UCL have identified the first blood test able to predict the onset and progression of Huntington’s disease (HD).
Read More
Teva’s Austedo wins US nod for Huntington’s patients
US regulators have green-lighted Teva Pharmaceutical Industries’ Austedo for the treatment of chorea associated with Huntington’s disease (HD), offering patients the first new treatment option in nearly a decade.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
